Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2014 | Pages:
87 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
UCB S.A. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'UCB S.A. - Product Pipeline Review - 2014', provides an overview of the UCB S.A.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of UCB S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of UCB S.A. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of UCB S.A.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the UCB S.A.'s pipeline products Reasons to buy - Evaluate UCB S.A.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of UCB S.A. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the UCB S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of UCB S.A. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of UCB S.A. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of UCB S.A. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 UCB S.A. Snapshot 6 UCB S.A. Overview 6 Key Information 6 Key Facts 6 UCB S.A. - Research and Development Overview 7 Key Therapeutic Areas 7 UCB S.A. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Pipeline Products - Out-Licensed Products 14 Out-Licensed Products/Combination Treatment Modalities 15 UCB S.A. - Pipeline Products Glance 16 UCB S.A. - Late Stage Pipeline Products 16 Pre-Registration Products/Combination Treatment Modalities 16 Filing rejected/Withdrawn Products/Combination Treatment Modalities 17 Phase III Products/Combination Treatment Modalities 18 UCB S.A. - Clinical Stage Pipeline Products 19 Phase II Products/Combination Treatment Modalities 19 Phase I Products/Combination Treatment Modalities 20 UCB S.A. - Early Stage Pipeline Products 21 Preclinical Products/Combination Treatment Modalities 21 Discovery Products/Combination Treatment Modalities 22 UCB S.A. - Drug Profiles 23 lacosamide 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 levetiracetam 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 certolizumab pegol 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 brivaracetam 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 epratuzumab 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 rotigotine 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 UCB-4940 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 CDP-7657 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 UCB-5857 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Antibody for Cancer, Immunology and Inflammation 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 VR-942 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Humanized Transglutaminase 2 Inhibitory Antibody 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 UCB S.A. - Pipeline Analysis 53 UCB S.A. - Pipeline Products by Target 53 UCB S.A. - Pipeline Products by Route of Administration 55 UCB S.A. - Pipeline Products by Molecule Type 56 UCB S.A. - Pipeline Products by Mechanism of Action 57 UCB S.A. - Recent Pipeline Updates 59 UCB S.A. - Dormant Projects 76 UCB S.A. - Discontinued Pipeline Products 78 Discontinued Pipeline Product Profiles 78 CDP-323 78 CDP-435 78 CDP-484 78 CDP-571 79 CDP-860 79 lacosamide 79 seletracetam 79 UCB-0942 79 UCB-2892 80 UCB S.A. - Company Statement 81 UCB S.A. - Locations And Subsidiaries 82 Head Office 82 Other Locations & Subsidiaries 82 Appendix 86 Methodology 86 Coverage 86 Secondary Research 86 Primary Research 86 Expert Panel Validation 86 Contact Us 87 Disclaimer 87
List of Tables UCB S.A., Key Information 6 UCB S.A., Key Facts 6 UCB S.A. - Pipeline by Indication, 2014 9 UCB S.A. - Pipeline by Stage of Development, 2014 10 UCB S.A. - Monotherapy Products in Pipeline, 2014 11 UCB S.A. - Partnered Products in Pipeline, 2014 12 UCB S.A. - Partnered Products/ Combination Treatment Modalities, 2014 13 UCB S.A. - Out-Licensed Products in Pipeline, 2014 14 UCB S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2014 15 UCB S.A. - Pre-Registration, 2014 16 UCB S.A. - Filing rejected/Withdrawn, 2014 17 UCB S.A. - Phase III, 2014 18 UCB S.A. - Phase II, 2014 19 UCB S.A. - Phase I, 2014 20 UCB S.A. - Preclinical, 2014 21 UCB S.A. - Discovery, 2014 22 UCB S.A. - Pipeline by Target, 2014 54 UCB S.A. - Pipeline by Route of Administration, 2014 55 UCB S.A. - Pipeline by Molecule Type, 2014 56 UCB S.A. - Pipeline Products by Mechanism of Action, 2014 58 UCB S.A. - Recent Pipeline Updates, 2014 59 UCB S.A. - Dormant Developmental Projects,2014 76 UCB S.A. - Discontinued Pipeline Products, 2014 78 UCB S.A., Subsidiaries 82
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
